NHS Grampian | NHS Highland | NHS Orkney | NHS Shetland | NHS Tayside | NHS Eileanan Siar Western Isles

Patient Group Direction For The Administration Of Hepatitis B Vaccine Renal Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles

Lead Author: Adapted from Public Health Scotland Administration Of Hepatitis B Vaccine Renal Indications Patient Group Direction (PGD) Template, Version 1.1 – PHS publication date 1st July 2025		**Approver:** NoS PGD Group **Authorisation:** NHS Grampian
Signature:		**Signature:**
NoS Identifier: NoS/PGD/HepB_Renal/ 1602	**Review Date:** 30th June 2028 **Expiry Date:** 30th June 2028	**Date Approved by NoS:** 7th July 2025

NHS Grampian, Highland, Orkney, Shetland, Tayside and Western Isles have authorised this Patient Group Direction to help individuals by providing them with more convenient access to an efficient and clearly defined service within the NHS Boards. This Patient Group Direction cannot be used until Appendix 1 and 2 are completed.

Uncontrolled when printed

Version 1.1

Revision History for NoS:

NoS PGD that has been superseded	NoS/PGD/HepB_Renal/1602, Version 1.0 (Unpublished due to amendment required from PHS)

Most recent changes NoS

Version	Date of change	Summary of Changes	Section heading
1.0	09 January 2025	Unpublished due to amendment required from PHS	
1.1	01 July 2025	Reference to NoS Appendix 1 and 2.	Authorisation
		Training requirements for NoS.	Continuing education and training
	03 July 2025	Admin issue	Inclusion criteria and frequency

PHS recent changes

Version	Date	Summary of changes
1.1	01 July 2025	The following changes have been made to V1.0 of this PGD. • Exclusion criteria: wording in relation to serological markers of current and previous infection updated and removal of Hepatitis B surface antibody (anti HBs) • Co-administration with other vaccines – wording added to highlight Fendrix off label use • Action if Excluded Section - updated in relation to individuals with serological markers of current or past infection • Dosage (table 1) and Use Outwith SmPC sections updated to detail HBVAXPRO40 off label use for those aged 16 and 17 years and UK Kidney Association guidance • UK Kidney Association Guidance added to Additional References section • Minor editing throughout to HBVAXPRO wording

Review date: The review date for a PGD needs to be decided on a case-by-case basis in the interest of safety. The expiry date should not be more than 3 years, unless a change in national policy or update is required.

Contents

Authorisation

This specimen Patient Group Direction (PGD) template has been produced by Public Health Scotland and adapted by North of Scotland PGD Group (NoS) to assist NHS Boards. NHS Boards should ensure that the final PGD is considered and approved in line with local clinical governance arrangements for PGDs.

The qualified health professionals who may administer vaccine under this PGD can only do so as named individuals. It is the responsibility of each professional to practice within the bounds of their own competence and in accordance with their own Code of Professional Conduct and to ensure familiarity with the manufacturer's product information/Summary of Product Characteristics (SmPC) for all vaccines administered in accordance with this PGD.

NHS Board governance arrangements will indicate how records of staff authorised to operate this PGD will be maintained. Under PGD legislation there can be no delegation. Administration of the vaccine has to be by the same practitioner who has assessed the patient under the PGD.

All authorised staff are required to read the PGD and sign the Agreement to Administer Medicines Under PGD (Appendix 1).

A Certificate of Authorisation (Appendix 2) signed by the authorising professional/manager should be supplied. This should be held in the individual health professional's records, or as agreed within the individual Health Board.

This PGD has been produced for NoS by:					
Doctor	William Moore	Signature		Date Signed	03/07/2025
Pharmacist	Fiona Marion	Signature		Date Signed	03/07/2025
Nurse	Elaine Maguire	Signature		Date Signed	01/07/2025

Approved for use within NoS by:

NoS Group Chair	**Signature**	**Date Signed**
Lesley Coyle		03/07/2025

Authorised and executively signed for use within NoS by:

NHS Grampian Chief Executive	**Signature**	**Date Signed**
Adam Coldwells – Interim Chief Executive		07/07/2025

Version 1.1 – Approved for NoS from 7th July 2025

1. Clinical Situation

1.1. Indication

Active immunisation of individuals who are 15 years of age or over and are on haemodialysis, a renal transplantation programme or have chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant in accordance with the recommendations given in Chapter 7 and Chapter 18 of Immunisation Against Infectious Disease: The Green Book.

1.2. Inclusion criteria

Individuals who:

- are 15 years of age or over and are on haemodialysis, a renal transplantation programme or have chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant

Valid consent has been given to receive the vaccine.

1.3. Exclusion criteria

Individuals who:

- are under 15 years of age
- have had a confirmed anaphylactic reaction to a previous dose of any hepatitis B containing vaccine or to any components of the vaccines (refer to relevant SmPC)
- are known to have positive serological markers, Hepatitis B surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBc IgM) indicating current infection or positive Anti-HBcore (hepatitis B core antibody) as a marker of past hepatitis infection
- have a history of severe (i.e. anaphylactic reaction) to latex where the vaccine is not latex free including syringe, tip and plunger
- are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation)

1.4. Cautions/need for further advice/circumstances when further advice should be sought from a doctor

The Green Book advises there are very few individuals who cannot receive hepatitis B-containing vaccines.

When there is doubt, appropriate advice should be sought from the immunisation co-ordinator or health protection team rather than withholding the vaccine.

The presence of a neurological condition is not a contraindication to immunisation but if there is evidence of current neurological deterioration, deferral of vaccination may be considered, to avoid incorrect attribution of any change in the underlying condition. The risk of such deferral should be balanced against the risk of the

preventable infection, and vaccination should be promptly given once the diagnosis and/or the expected course of the condition becomes clear.

Co-administration of other vaccines

Hepatitis B vaccines can be given at the same time as other vaccines. When administering at the same time as other vaccines, care should be taken to ensure that the appropriate route of injection is used for all the vaccinations. The vaccines should be given at separate sites, preferably in different limbs. If given in the same limb, they should be given at least 2.5cm apart. The site at which each was given should be noted in the individual's records.

However, when other vaccines are given at the same time as Fendrix®, this is off-label (See Is the use outwith the SmPC section).

Syncope

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

Pregnancy and breastfeeding

There is no evidence of risk from vaccinating pregnant women or those who are breast feeding with inactivated vaccines. Since hepatitis B vaccine is an inactivated vaccine, the risks to the foetus are negligible and it should be given where there is a definite risk of infection.

1.5 Action if excluded

Specialist advice must be sought on the vaccine and circumstances under which it could be given. Immunisation using a patient specific direction may be indicated.

The risk to the individual of not being immunised must be taken into account.

Document the reason for exclusion and any action taken in accordance with local procedures.

Inform or refer to the clinician in charge.

Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Individuals who are under 15 years of age who are on haemodialysis, renal transplantation programmes or with chronic renal failure (CKD stage 4 or 5) that is likely to require haemodialysis or transplant, should be referred for specialist advice

on the appropriate vaccination schedule. A PSD is required as vaccination of these individuals is outside the remit of this PGD.

Individuals known to have markers of current (HBsAg) or past (anti-HBcore) hepatitis B infection should be advised that vaccination is not necessary. However, immunisation should not be delayed while awaiting any test results.

Temporary exclusion

In case of postponement due to acute severe febrile illness, arrange a future date for immunisation.

1.6. Action if patient declines

Advise the individual about the protective effects of the vaccine, the risks of infection and potential complications of disease.

Advise how future immunisation may be accessed if they subsequently decide to receive the vaccine.

Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Document advice given and decision reached.

Inform or refer to the clinician in charge.

2. Description of Treatment

2.1. Name of medicine/form/strength

Hepatitis B recombinant DNA (rDNA) vaccine (adsorbed) (HepB)

- **Engerix B®** 20micrograms/1ml suspension for injection in prefilled syringe
- **Fendrix®** 20micrograms/0.5ml suspension for injection in prefilled syringe
- **HBVAXPRO®** 40micrograms/1ml suspension for injection in a vial
- **HEPLISAV B®** 20micrograms/0.5ml solution for injection in prefilled syringe

Evidence supports the use of Fendrix® over Engerix B® in people with chronic kidney failure but strong evidence is lacking to recommend other vaccines over Fendrix® in this group, as other vaccines such as HEPLISAV B® have mainly been compared to Engerix B® only.

2.2. Route of administration

Hepatitis B-containing vaccines are routinely given intramuscularly in the upper arm or anterolateral thigh. For individuals with a bleeding disorder, vaccines normally given by an intramuscular route should be given in accordance with the recommendations in the Green Book Chapter 4.

The vaccine should be visually inspected for particulate matter and discoloration prior to administration.

In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine.

2.3. Dosage

Current UK licensed Hep B vaccines contain different concentrations of antigen per millilitre.

Table 1: Current UK licensed Hep B vaccine doses for adolescents and adults with renal insufficiency including dialysis

Age	Vaccine	Dose	Volume
Individuals with renal insufficiency aged 15 years and over	Fendrix®	20 micrograms	0.5 ml
16 years and over dialysis and pre-dialysis individuals*	HBVAXPRO®	40 micrograms	1.0 ml
Individuals with renal insufficiency and dialysis individuals aged 16 years and over	Engerix B®	2 x 20 micrograms	2 x 1.0 ml
Individuals with severe renal impairment (eGFR < 30ml/min) including patients undergoing haemodialysis aged 18 years and over	HEPLISAV B®	20 micrograms	0.5 ml

* The SmPC for HBVAXPRO 40micrograms recommends use of the vaccine in adults. However, the vaccine can be used off-label to administer the vaccine to 16 to 17 years old (included) in accordance with the guidelines from the UK Kidney Association. (see Is the use out with SmPC section)

2.4. Frequency

Table 2: Schedule for adolescents and adults with renal insufficiency including dialysis

Schedule	Examples of when to use this schedule
Fendrix 20micrograms / 0.5ml: • 4 doses at 0 then 1, 2 and 6 months after the first dose	Use for individuals from 15 years of age.
HBVAXPRO 40micrograms / 1.0ml: • 3 doses at 0 then 1 and 6 months after the first dose	Use for individuals from 16 years of age.
Engerix B 20micrograms / 1.0ml: • 4 double doses (2 x 20 micrograms) at 0 then 1, 2, 6 months after the first dose	Use for individuals from 16 years of age.
HEPLISAV B 20 micrograms/0.5ml: • 4 doses at 0,1,2 and 4 months after the first dose	Use for individuals from 18 years of age with severe renal impairment (eGFR < 30ml/min) including patients undergoing haemodialysis
Booster (Fendrix 20micrograms / 0.5ml, HBVAXPRO 40micrograms / 1.0ml or Engerix B 20micrograms / 1.0ml): • single dose administered if anti-HBs levels fall below 10mIU/ml in an individual who has previously responded to the vaccine (levels should be monitored annually) • single dose to haemodialysis patients travelling to highly endemic areas if they have not received a booster in the last 12 months The need for a booster dose has not been established for HEPLISAV B. Specialist advice should be sought where antibody levels have decreased below recommended levels. Where a booster dose is recommended, the administration of booster doses is covered under this PGD, noting this product is licensed from 18 years and above.	Individuals on haemodialysis: From 15 years of age Fendrix From 16 years of age HBVAXPRO 40 micrograms or Engerix B

Where immunisation has been delayed beyond the recommended intervals, the vaccine course should be resumed but not repeated.

HBVAXPRO 40 micrograms and Engerix B may be used interchangeably to complete the vaccine course. Once the primary immunisation schedule has been started with Fendrix, interchanging with other brands of hepatitis B vaccine is off-label.

2.5. Duration of treatment

See frequency section.

2.6. Maximum or minimum treatment period

See frequency section.

2.7. Quantity to supply/administer

See frequency section.

2.8. ▼ black triangle medicines

Yes, HEPLISAV B. The Medicines and Healthcare products Regulatory Agency (MHRA) has a specific interest in the reporting of adverse drug reactions for newly approved vaccines. All suspected adverse drug reactions should be reported using the MHRA Yellow Card Scheme.

2.9. Legal category

Prescription only medicine (POM).

2.10. Is the use outwith the SmPC?

Administration of Fendrix by deep subcutaneous injection to patients with a bleeding disorder is off-label administration in line with advice in Chapter 4 and Chapter 18 of the Green Book.

Once the primary immunisation schedule has been started with Fendrix, interchanging with other brands of hepatitis B vaccine is off label.

The SmPC for HBVAXPRO 40micrograms recommends use of the vaccine in adults. However, the vaccine can be used off-label to administer the vaccine to 16 to 17 years old (included) in accordance with the guidelines from the UK Kidney Association.

Recommendations in the Green Book Chapter 18 allow for concomitant administration of hepatitis B vaccine with other vaccines at a separate site when required. For Fendrix, such administration would be off-label as, due to a lack of data, the SmPC for Fendrix advises an interval of 2 to 3 weeks be respected between the administration of Fendrix and other vaccines. The SmPC for HEPLISAV B

advises that the concomitant use with other vaccines is not recommended. This is superseded by the advice in the Green Book Chapter 18.

Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the vaccine is being offered in accordance with national guidance but that this is outside the product licence.
Vaccine should be stored according to the conditions detailed below.

However, in the event of an inadvertent or unavoidable deviation of these conditions refer to NHS Board guidance on storage and handling of vaccines or national vaccine incident guidance.

Where vaccine is assessed in accordance with these guidelines as appropriate for continued use, administration under this PGD is allowed.

2.11. Storage requirements

Vaccine should be stored at a temperature of +2° to +8°C.

Store in the original packaging to protect from light.

Do not freeze.

NHS Board guidance on Storage and Handling of vaccines should be observed.

In the event of an inadvertent or unavoidable deviation of these conditions, vaccine that has been stored outside the conditions stated above should be quarantined and risk assessed for suitability of continued off-label use or appropriate disposal.

2.12. Additional information

Minor illnesses without fever or systemic upset are not valid reasons to postpone immunisation. If an individual is acutely unwell, immunisation may be postponed until they have fully recovered.

Immunological response may be diminished in those receiving immunosuppressive treatment.

Because of the long incubation period of hepatitis B, it is possible for unrecognised infection to be present at the time of immunisation. The vaccine may not prevent hepatitis B infection in such cases.

The vaccine will not prevent infection caused by other pathogens known to infect the liver such as hepatitis A, hepatitis C and hepatitis E viruses.

Testing for evidence of infection or immunity

Additional vaccine doses may need to be considered for individuals who do not respond or have a sub-optimal response to a course of vaccinations. See Table 2

Booster doses and refer to Chapter 18 of the Green Book for advice on response to vaccine and the use of additional doses.

3. Adverse reactions

3.1. Warnings including possible adverse reactions and management of these

For full details/information on possible side effects, refer to the marketing authorisation holder's SmPC.

Hepatitis B vaccine is generally well tolerated and the most common adverse reactions are soreness and redness at the injection site. Other reactions that have been reported but may not be causally related include fever, rash, malaise and an influenza-like syndrome, arthritis, arthralgia, myalgia and abnormal liver function tests. Headache is a very common reaction to HEPLISAV B® vaccine.

As with all vaccines there is a very small possibility of anaphylaxis and facilities for its management must be available.

In the event of severe adverse reaction individual should be advised to seek medical advice.

3.2. Reporting procedure for adverse reactions

Healthcare professionals and individuals/carers should report all suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on http://www.mhra.gov.uk/yellowcard.

Any adverse reaction to a vaccine should be documented in accordance with locally agreed procedures in the individual's record and the individual's GP should be informed.

3.3. Advice to patient or carer including written information

Written information to be given to individuals:

- Provide manufacturer's consumer information leaflet/patient information leaflet (PIL) provided with the vaccine.
- Supply immunisation promotional material as appropriate.

Individual advice/follow-up treatment:

- Inform the individual/carer of possible side effects and their management
- The individual should be advised to seek medical advice in the event of a severe adverse reaction.
- Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme.
- When applicable, advise individual/parent/carer when the subsequent dose is due.

- Advise individuals of preventative measures to reduce exposure to hepatitis B (such as avoiding exposure to blood and bodily fluids).

Individuals/carers should be informed about the importance of completing a course of hepatitis B immunisation.

3.4. Observation following vaccination

Following immunisation, patients remain under observation in line with NHS Board policy.

As syncope (fainting) can occur following vaccination, all vaccinees should either be driven by someone else or should not drive for 15 minutes after vaccination.

3.5. Follow up

As above.

3.6. Additional facilities

A protocol for the management of anaphylaxis and an anaphylaxis pack must always be available whenever vaccines are given. Immediate treatment should include early treatment with intramuscular adrenaline, with an early call for help and further IM adrenaline every 5 minutes.

The health professionals overseeing the immunisation service must be trained to recognise an anaphylactic reaction and be familiar with techniques for resuscitation of a patient with anaphylaxis.

4. Characteristics of staff authorised under the PGD

4.1. Professional qualifications

The following classes of registered healthcare practitioners are permitted to administer this vaccine:

- nurses and midwives currently registered with the Nursing and Midwifery Council (NMC)
- pharmacists currently registered with the General Pharmaceutical Council (GPhC)
- pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC)
- chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC)
- dental hygienists and dental therapists registered with the General Dental Council
- optometrists registered with the General Optical Council.

4.2. Specialist competencies or qualifications

Persons must only work under this PGD where they are competent to do so.

All persons operating this PGD:

- demonstrate appropriate knowledge and skills to work under this PGD.
- must be authorised by name by their employer as an approved person under the current terms of this PGD before working to it.
- must be familiar with the vaccine product and alert to changes in the manufacturer's product information/SmPC.
- must be competent to undertake immunisation and to discuss issues related to immunisation to assess patients for vaccination and obtain consent.
- must be competent in the correct storage of vaccines and management of the cold chain if receiving, responsible for, or handling the vaccine.
- must be competent in the recognition and management of anaphylaxis or under the supervision of persons able to respond appropriately to immediate adverse reactions.
- must have access to the PGD and associated online resources.
- should fulfil any additional requirements defined by local policy.

Employer

The employer is responsible for ensuring that persons have the required knowledge and skills to safely deliver the activity they are employed to provide under this PGD.

As a minimum, competence requirements stipulated in the PGD must be adhered to.

4.3. Continuing education and training

All practitioners operating under the PGD are responsible for ensuring they remain up to date with the use of vaccines included. If any training needs are identified these should be discussed with the individuals in the organisation responsible for authorising individuals to act under this PGD.

- Have undertaken NoS PGD module training on TURAS Learn
- Have attended basic life support training either face to face or online and updated in-line with individual Board requirements
- Have undertaken immunisation training where available
- Have undertaken NHS e-anaphylaxis training or equivalent which covers all aspects of the identification and management of anaphylaxis updated in-line with individual Board requirements
- Maintain their skills, knowledge and their own professional level of competence in this area according to their individual Code of Professional Conduct.

5. Audit trail

Record the following information:

- valid informed consent was given
- name of individual, address, date of birth and GP with whom the individual is registered if possible
- name of person that undertook assessment of individual's clinical suitability and subsequently administered the vaccine
- name and brand of vaccine
- date of administration
- dose, form and route of administration of vaccine
- batch number
- where possible expiry date
- anatomical site of vaccination
- advice given, including advice given if excluded or declines immunisation
- details of any adverse drug reactions and actions taken
- administered under PGD

Records should be kept in line with local procedures

Local policy should be followed to encourage information sharing with the individual's General Practice

All records should be clear, legible and contemporaneous and in an easily retrievable format.

6. Additional references

Practitioners operating the PGD must be familiar with:

- Immunisation against Infectious Disease [Green Book]
- Immunisation against infectious disease - Chapter 18 - Hepatitis B
- current edition of British National Formulary.
- Marketing authorisation holders Summary of Product Characteristics.
- Professional Guidance on the Administration of Medicines in Healthcare settings 2019.
- Professional Guidance on the Safe and Secure Handling of Medicines.
- Clinical Practice Guideline Management of Blood Borne Viruses within the Haemodialysis Unit
- Educational resources for registered professionals produced by National Education for Scotland

7. Version history

Version	Date	Summary of changes
1.0	6 January 2025	New PGD
1.1	01 July 2025	The following changes have been made to V1.0 of this PGD. • Exclusion criteria: wording in relation to serological markers of current and previous infection updated with removal of Hepatitis B surface antibody (anti HBs) • Co-administration with other vaccines – wording added for Fendrix and off label use • Action if excluded section - updated in relation to individuals with serological markers of current or past infection • Dosage (table 1) and Use Outwith SmPC sections updated to detail HBVAXPRO40 off label use for those aged 16 and 17 years and UK Kidney Association guidance • UK Kidney Association Guidance added to Additional References section • Minor editing throughout to HBVAXPRO wording

Version History NoS

Version	Date of change	Summary of Changes	Section heading
1.0	09 January 2025	Unpublished due to amendment required from PHS	
1.1	01 July 2025	Reference to NoS Appendix 1 and 2.	Authorisation
		Training requirements for NoS.	Continuing education and training
	03 July 2025	Admin issue	Inclusion criteria and frequency

Appendix 1 - Healthcare Professional Agreement to Administer Medicine(s) Under Patient Group Direction

I: _____ (Insert name)

Working within: _____ e.g. Area, Practice

Agree to administer the medicine(s) contained within the following Patient Group Direction:

Patient Group Direction For The Administration Of Hepatitis B Vaccine Renal Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles, Version 1.1

I have completed the appropriate training to my professional standards enabling me to administer the medicine(s) under the above direction. I agree not to act beyond my professional competence, nor out with the recommendations of the direction.

Signed: _____

Print Name: _____

Date: _____

Profession: _____

Professional Registration number/PIN: _____

NHS Grampian NHS Highland NHS Orkney NHS Shetland NHS Tayside NHS Eileanan Siar Western Isles

Appendix 2 - Healthcare Professionals Authorisation to Administer Medicine(s) Under Patient Group Direction

The Lead manager/Professional of each clinical area is responsible for maintaining records of all clinical areas where this PGD is in use, and to whom it has been disseminated.
The Senior Nurse/Professional who approves a healthcare professional to administer the medicine(s) under this PGD is responsible for ensuring that they are competent, qualified and trained to do so, and for maintaining an up-to-date record of such approved persons.
The Healthcare Professional that is approved to administer the medicine(s) under this PGD is responsible for ensuring that they understand and are qualified, trained and competent to undertake the duties required. The approved person is also responsible for ensuring that administration is carried out within the terms of the direction, and according to their individual code of professional practice and conduct.
Patient Group Direction For The Administration Of Hepatitis B Vaccine Renal Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles, Version 1.1
Local clinical area(s) where the listed healthcare professionals will operate under this PGD:

Name of Healthcare Professional	Signature	Date	Name of Manager	Signature	Date

Patient Group Direction For The Administration Of Hepatitis B Vaccine Renal Indications By Approved Healthcare Professionals Working Within NHS Grampian, Highland, Orkney, Shetland, Tayside And Western Isles, Version 1.1					
Name of Healthcare Professional	**Signature**	**Date**	**Name of Manager**	**Signature**	**Date**